Object: The potential effects of branched-chain amino acids (BCAAs)on spinocerebellar degeneration (SCD) were explored in eleven patients. Methods: The patients received 200 ml of BCAA-rich solution, 2 mg of thyrotropin-releasing hormone (TRH; protirelin), or a placebo daily for 7 days each in a random order. An SCDscore was used to quantify the severity of symptoms. Patients: Eleven patients with SCD(7 male, 4 female; mean age 60±ll; mean disease duration 5.5 years) participated in this study. Results: The meanSCDscore of the eleven patients improved significantly by the BCAAtreatment compared with the baseline. The conditions of five of the eleven patients (45 %) were clearly improved by the BCAAtreatment. All of the responders manifested predominantly cerebellar symptoms, but no prominent parkinsonian symptoms. Two patients with marked rigidity and akinesia did not respond to the treatment. Conclusion: Weconcluded that BCAAsdo have a beneficial effect on functional improvement in patients with SCD, and that further large scale studies are needed. (Internal Medicine 38: 401-406, 1999) 
Introduction
Degeneration and loss of cerebellar neurons including Purkinje cells and granule cells are the main cause of spinocerebellar degeneration (SCD). Many studies have been performed to design a treatment protocol for SCD (1) (2) (3) , but few satisfactory therapies have been established. Thyrotropin-releasing hormone (TRH) has had a central role in SCDtreatments, and several studies of this agent have been conducted (1, 3, 4) . However, its effectiveness varies with the type or severity of disease, and someinvestigators report that TRHhas no significant effect compared with a placebo (4) . Wehave been searching for a novel therapy to slow or halt cerebellar degeneration and to recover motor function. Although excess glutamate has excitatory neurotoxicity in the extracellular fluid, glutamate is an important neurotransmitter between cerebellar granule cells and Purkinje cells. Wehave speculated that stimulation of intracellular glutamate metabolism may improve the neurotransmission of cerebellar neurons. In other words, administration of amino acids that supply the amino group in glutamate synthesis may improve motor function and inhibit neuronal degeneration. Branched-chain amino acids (BCAAs), as described by Yudkoff, are the most suitable amino acids for this purpose (5) . Weevaluated the potential neurotrophic effects of BCAAs using rat primary cerebellar cultures, and observed that BCAAtreatment significantly increases neuronal survival in vitro (6) . This result indicated the potential beneficial effects of BCAAs for SCD. Thus, we carried out a single-blind triple-crossover trial of BCAAtherapy in patients with SCD.
Subjects and Methods
Eleven patients participated in this study ( Case no.  1  2  3  4  5  6  7  8  9  10  ll   Clinical  Sex  M  M  M  F  M  F  F  M  M  M  F  features  Age  47  72  57  44  70  67  67  70  52  68  50  Age of onset  46  69  5 1  43  61  63  5 1  59  48  64  49  Stage  I  I  II  II  II  II  III  III  III  IV Aminoleban®is widely used for the treatment of hepatic encephalopathy ( Table 2 ). The patients were masked with respect to which treatment they were receiving at a given time. SCDscoring was created, and has been utilized, in our ward for the clinical assessment of SCDbased on the Ataxia Evaluation Manual in a multi-center, placebo-controlled double-blind study of thyrotropin releasing hormone tartrate (TRH-T) ( 1). Patients were scored before commencing(baseline) and fol- BCAATherapy for SCD lowing treatment in order to quantify the severity of, and changes in, clinical symptoms. For all scale items, scoring ranged from 0 (normal) to 45 (poorest performance). The posturography method was used to document and quantify truncal ataxia, except for the wheelchair-bound patients. The parameters of trace length per environ area of sway (L/E area) and root meansquare area (RMSarea) were used for the evaluation with a static posturographic platform (stabilometry)
Gravicorder® (Anima, Japan). Clinical symptoms, SCDscores, and posturography measurementswere evaluated after each seven-day treatment. Serum and cerebrospinal fluid (CSF) amino acids were analyzed at the baseline and at the end of the BCAAtreatment phase.
Results
Analysis of 1 1 cases Five of the eleven patients showeddefinite subjective and objective improvement after BCAAtreatment (effective ratio 45.5%). Five patients showed no remarkable change (45.5%), and the condition of one patient worsened (9.0%). The responders were all at the mild or moderate (1 through 3) stages. The moderate cases showed definite improvement after treatment with BCAA,while the milder or more severe cases had no similar improvement (Fig. 1) . For the total patient series, the mean SCDscore at the baseline was 20.718.8 (meaniSE), which improved significantly to 18.6±8.1 following BCAA treatment ( Fig. 2: analysis of variance (ANOVA)p<0.02, post hoc p<0.05). Differences among the control, TRH, and BCAA treatments were not significant.
In the nine items of SCDscore, only hand-writing, that is, drawing spirals and tracing mazes, showed obvious improvement after BCAAtreatment (Fig. 3: paired Wilcoxon test p<0.05). Neither posturography measurementsnor aminoacid content of serum or CSFshowed significant change over the study duration (Figs. 4 and 5) . The concentration of CSF glutamate was not detectable in four patients and traces were observed in two others. Five patients, four men and one woman(mean age; 67.2±6.0 years), responded to BCAAtherapy. The mean period of the disease for these patients was 9.0±5.0 years. Their clinical types were variable; two cases of hereditary cerebellar ataxia (SCA 1, SCA6), two OPCAand one LCCA. All manifested predominantly cerebellar symptoms, but no prominent symptoms of parkinsonism. The SCDscores of the responders were 18.8±5.6 at the baseline, 18.2±5.4 after control, 18.4±6.0 after TRH, and 15.6±4.8 after BCAAtreatment (Fig. 6 ). Significant changes were observed between BCAAand baseline, BCAA and control, and BCAAand TRH (ANOVA<0.02, post hoc ers (n=2) respectively, and an X represents the patient whose condition worsened. After BCAA treatment, the time standing on one foot (right+left) improved in seven patients, the time to repeat a sentence three times ('Ruri moHari moTeraseba Hikaru' in Japanese) improved in ten, drawing spirals on predrawnpatterns and tracing mazesin nine, and heel-shin test in six patients. Of the nine componentsof the SCDscore, only handwriting, that is, drawing spirals and tracing mazes, showed obvious improvement after BCAAtreatment (paired Wilcoxon test p<0.05). Lower scores indicate better performance in all items except standing.
(nmol/ml) (nmol/ml) , and the non-responders (n=2) respectively. After administration of BCAA, concentrations of valine, leucine, and isoleucine seemedto becomeelevated, but there were no significant differences between before and after the treatment.
p<0.05), but not between baseline, control, and TRHscores (Fig.6) .
A case report Here wepresent a patient with remarkable effects after BCAAtherapy. A woman, aged 66, developed gait disturbance and dysarthria at age 48, and was diagnosed as having LCCA at age 56. She had no family history of ataxia and there was nothing particularly noticeable in her medical or life history. Neurologically, she showed scanning and explosive speech, blurred vision with gazing nystagmus, cerebellar ataxia including limb ataxia, dysdiadochokinesis, dysmetria, intentional tremor of fingers, and ataxic gait. Deep tendon reflexes were normal and no rigidity was observed. The CAGrepeat of ocIAsubunit-voltage-dependent calcium channel was extended to 22, and the patient was diagnosed as having SCA6. She was classified as stage 3. Her SCDscores were 24 at baseline, 24 after control, 25 after TRHtreatment, and 19 after BCAAtreatment. BCAAadministration markedly improved her SCDscore. She was able to walk more easily after the BCAA feedings, and her ataxic symptoms significantly improved both subjectively and objectively, especially regarding discrete movements such as speed of handwriting and tapping. The time required to trace pre-drawn spirals and mazes improved by 1 16 seconds after BCAAtreatment, compared with 2 16 seconds at baseline. Her posturography also markedly changed: the RMSarea (mean 
Discussion
Aminoacids that supply the amino group in glutamate synthesis in the central nervous system must satisfy the following criteria: (a) the donor amino acid must transport rapidly across the blood-brain barrier, (b) the donor itself must not be neuroactive, i.e., it must safely "travel" throughout the brain extracellullar fluid and not evoke depolarization, and (c) the amino group of the donor must be readily transferred to aketoglutarate, via transamination catalyzed by an enzymeabundant in the nervous system (5). Branched-chain amino acids can serve this metabolic and nutritional role. Thus, BCAA therapy maybe expected to have some effect on the functional recovery of neurodegenerative diseases. BCAAadministration significantly increased the survival of cultured cerebellar neurons (6) , which suggests that BCAAs may act as a neuroprotective agent for cerebellar neurons. The use of BCAAs to buffer extracellular glutamate pools and as a treatment in patients with amyotrophic lateral sclerosis has been reported (8-1 1), however, we could find no such report on the effect of BCAAs on SCD. For evaluation, we adopted the SCDscore, established for clinical evaluations of the symptoms of SCDpatients based on the ataxia evaluating manual of TRH-Tin a multi-center, placebo-controlled double blind study (1) . The International Cooperative Ataxia Rating Scale, which the Ataxia Neuropharmacology Committee of the World Federation of Neurology proposed for the pharmacological assessment of cerebellar ataxia, was not yet available at the commencement of this trial (12) . In our trial, patients whoshowed improvementwere at the mild or moderate stages. For this reason, it is likely that the severe-stage patients had few surviving Purkinje cells and could not, therefore, respond to the stimulated glutamate release. In addition, little response was evoked from TRHtherapy, which has been reported to have a beneficial effect on SCDin many studies. This lack of response may be due in part to the fact that the TRHwas administered only for one week; as its recommended regimen is for a two-week period (1, 3, 4) . While there was no significant difference between the placebo (control) and TRH or BCAAtreatments, the BCAAtherapy showed a significant improvement in SCDscores relative to baseline (Fig. 2) . The responders showedpredominant cerebellar symptoms but no prominent parkinsonism. The patients with marked rigidity and akinesia (Cases 9 and 10) did not respond to the treatment. Large neutral amino acids (LNAAs)are known to compete with levodopa for transport across the blood-brain barrier (13) . The BCAAs,valine, leucine and isoleucine, belong to this category of amino acids. Therefore, patients who respond to levodopa therapy are likely to experience an exacerbation of parkinsonian symptoms due to elevated plasma BCAAlevels. BCAAs, which are absorbed rapidly after injection, are distributed throughout the central nervous system and muscle, where they readily undergo metabolic changes. The BCAA concentration in the CSFdoes not necessarily reflect its importance in the central nervous system. Extracellular glutamate is also distributed at varying concentrations in the CSF (highest in the synapse cleft) and may be taken up rapidly. The CSF obtained by lumbar puncture may not accurately reflect the central nervous system BCAAconcentration. In this trial, we investigated the functional recovery of SCD patients with a short-term administration of BCAA, and we are thus not able to evaluate its effect on slowing the progression of the disease. Fromthe results of this study, a long-term oral treatment with BCAAin patients with SCD seems prudent. For a short-term trial, an intravenous administration of BCAAmay be a beneficial therapy for moderate stage patients (Stages 2 and 3) with the cerebellar-predominant form of SCD. In conclusion, the clinical symptomsand SCDscores were significantly improved by BCAAtreatment compared with baseline. Five of eleven patients with SCD(45.4%) responded to the BCAAtreatment. BCAAis a promising agent for the treatment of patients with SCD, especially for their cerebellar symptoms.Large-scale and long term studies are necessary to further investigate the efficacy of BCAAtreatment. 
